Actinium Pharmaceuticals filings document governance and public-company reporting for a biopharmaceutical issuer whose common stock is registered on the NYSE American under ATNM. Recent Current Reports and proxy materials cover annual meeting matters, Class III director elections, advisory votes on executive compensation, principal financial officer changes, and registered common stock details.
The company's proxy disclosures connect shareholder voting matters with board structure, compensation oversight, and annual-report materials. Form 8-K filings record material events and amendments to prior event reports, including officer-transition disclosures and the final reporting of annual meeting voting outcomes.
Actinium Pharmaceuticals, Inc. granted Chief Financial Officer Matthew T. David 250,000 restricted stock units (RSUs) and options to purchase 250,000 common shares on October 14, 2026, under its 2026 Employment Inducement Award Plan. Of the RSUs, 125,000 vest in three equal installments on the first, second, and third anniversaries, and 125,000 vest in full on the third anniversary; both schedules require continued service. The options have a $0.975 exercise price and expire October 14, 2036. Twenty-eight percent vest 12 months after the grant date and 2% each month thereafter, subject to continued service on each vesting date.
Actinium Pharmaceuticals, Inc. (ATNM) scheduled its 2026 Annual Meeting for November 25, 2026, at 9:30 a.m. Eastern Time, at The Garden City Hotel in Garden City, New York. Stockholders will vote on electing David Nicholson and Richard I. Steinhart to three-year director terms, ratifying CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal 2026, and approving named executive officer compensation on a non-binding advisory basis. The Board unanimously recommends voting FOR all three proposals.
Stockholders of record on October 2, 2026 may vote. Actinium reported 31,441,436 common shares issued and outstanding on that date, with one vote per share; a quorum requires at least 34% of voting power. Matt David became CFO in October 2026 after Steve O’Loughlin resigned in February 2026. For 2025, CEO Sandesh Seth’s total compensation was $1,187,320 and former CFO O’Loughlin’s was $546,437. On September 2, 2026, Seth was granted options to purchase 1,130,400 shares and issued RSU awards of 735,600 and 1,027,274 shares, with different vesting schedules.
Actinium Pharmaceuticals, Inc. appointed Matt David, M.D. as chief financial officer and principal financial officer on October 14, 2026. His offer letter provides an annual base salary of $450,000, a target annual performance bonus of 40% of base salary and a $150,000 sign-on bonus. He will also receive a guaranteed prorated target bonus for 2026, subject to continued employment through the applicable payment date.
In connection with the appointment, David received an option to purchase 250,000 shares and 325,000 restricted stock units under the 2026 Employment Inducement Award Plan. The option’s exercise price equals the closing market price on the grant date and it vests over four years; the RSUs have time-based and performance-based vesting tied to corporate milestones. The offer letter also provides severance benefits for certain qualifying terminations, with enhanced benefits for certain terminations following a change in control.
Actinium Pharmaceuticals, Inc. (ATNM) reported the initial equity holdings of Chief Scientific Officer Kamal Adeela. The filing lists 213,648 shares of Common Stock in the form of restricted stock units and stock options over 120,000 shares of Common Stock.
Of the restricted stock units, 80,000 vest in three equal installments on September 2, 2027, September 2, 2028 and September 2, 2029, and 133,648 vest on September 2, 2029. The stock options have an exercise price of $1.00 per share, vest in fifty equal monthly tranches beginning on October 2, 2026, and expire on September 2, 2036.
Actinium Pharmaceuticals, Inc. (ATNM) reported the initial beneficial ownership of its Chief Medical Officer, Steffen Wilhem Heeger, on a Form 3. Heeger holds 153,868 shares of Common Stock in the form of restricted stock units that vest fully on September 2, 2029, and a stock option for 250,000 shares of Common Stock with an exercise price of $1.15 per share, expiring May 28, 2036. According to the disclosure, 28% of these options vest on May 28, 2027, with the remainder vesting in 36 equal monthly tranches thereafter.
Actinium Pharmaceuticals, Inc. (symbol: ATNM) is the issuer of record for a Form 4 filing submitted to the SEC. Shetty Ajit reported acquisition or exercise transactions in this Form 4 filing.
Actinium Pharmaceuticals, Inc. (ATNM) reported that director Ajit Shetty received equity awards on September 2, 2026. He was granted 61,600 shares of Common Stock as restricted stock units, which vest in three equal annual installments, and 92,400 stock options exercisable at $1.00 per share that vest in fifty equal monthly tranches. Following these awards, he holds 62,357 shares of Common Stock directly and 92,400 stock options. No Rule 10b5-1 trading plan is reported.
Actinium Pharmaceuticals, Inc. (ATNM) reported that director C. David Nicholson received equity awards on September 2, 2026. He was granted 62,800 shares of Common Stock in the form of restricted stock units that vest in three equal annual installments over three years. He also received a stock option for 94,200 shares of Common Stock at an exercise price of $1.00 per share, vesting in fifty equal monthly tranches and expiring on September 2, 2036. Following these awards, he holds 63,300 shares of Common Stock directly.
Actinium Pharmaceuticals, Inc. (symbol: ATNM) is the issuer of record for a Form 4 filing submitted to the SEC. Almenoff June Sherie reported acquisition or exercise transactions in this Form 4 filing.
Actinium Pharmaceuticals, Inc. (ATNM) reported that director June Sherie Almenoff received equity awards on September 2, 2026 under a Rule 10b5-1 trading plan. She was granted 18,000 shares of common stock in the form of restricted stock units and 27,000 stock options to buy common shares at $1.00 per share.
The restricted stock units vest in three equal annual installments over three years, and the options vest in fifty equal monthly installments beginning on the grant date and expire on September 2, 2036. Following these awards, she directly holds 18,000 common shares and 27,000 options related to these grants.